Nexstim Plc issues shares in standby equity distribution agreement pursuant to the financing arrangement announced on 21 July 2016, 11 November 2016

11 November 2016

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “Company”), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that, pursuant to the authorisations received at the Company's extraordinary general meeting on 18 August 2016 and the financing arrangement entered into with Bracknor Investment and the Finnish Innovation Fund Sitra which was announced on 21 July 2016, the Board of Directors of the Company has today resolved on issuing 2,231,545 shares to Bracknor with a subscription price of EUR 499,999.97 based on the stand-by equity distribution agreement (SEDA). The Board of Directors of the Company has also decided to list the issued new shares. The new shares will be listed approximately on 16 November 2016. After the issuance, the total number of registered shares in the Company will be 19,580,709.

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim +447715163942

Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com

UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246

Consilium Strategic Communications +44 (0)20 3709 5700

Mary-Jane Elliott / Ivar Milligan nexstim@consilium-comms.com

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com